NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Orion Oyj (HE: ORNBV)

 
ORNBV Technical Analysis
5
As on 7th Feb 2025 ORNBV STOCK Price closed @ 52.40 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 37.89 & Strong Buy for SHORT-TERM with Stoploss of 37.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ORNBVSTOCK Price

Open 52.20 Change Price %
High 52.60 1 Day -0.08 -0.15
Low 51.66 1 Week 0.64 1.24
Close 52.40 1 Month 10.15 24.02
Volume 264805 1 Year 17.11 48.48
52 Week High 52.56 | 52 Week Low 32.27
 
HE Finland Most Active Stocks
NOKIA 4.66 0.87%
NDA-FI 11.59 0.09%
YIT 2.13 -15.48%
STERV 10.49 -3.05%
OUT1V 3.19 0.63%
FORTUM 14.16 2.61%
MOCORP 10.22 -2.29%
NESTE 11.70 -0.17%
TYRES 6.29 -1.26%
UPM 27.86 -2.69%
 
HE Finland Top Gainers Stocks
VALOE 0.93 5.68%
KCR 63.00 5.44%
KCR 63.00 5.44%
TEM1V 4.55 5.32%
OKDAV 0.99 4.21%
ROBIT 1.39 3.73%
FSC1V 5.00 3.52%
ILK1S 4.92 3.36%
FSKRS 15.68 3.29%
VERK 1.70 3.03%
 
HE Finland Top Losers Stocks
YIT 2.13 -15.48%
YIT 2.13 -15.48%
YIT 2.13 -15.48%
YIT 2.13 -15.48%
YIT 2.13 -15.48%
LOUD 0.10 -9.09%
ACG1V 3.31 -6.50%
SOLTEQ 0.60 -6.25%
FELLOW 0.32 -5.88%
AFAGR 0.34 -5.56%
 
 
ORNBV
Daily Charts
ORNBV
Intraday Charts
Whats New @
Bazaartrend
ORNBV
Free Analysis
 
ORNBV Important Levels Intraday
RESISTANCE54.21
RESISTANCE53.63
RESISTANCE53.27
RESISTANCE52.91
SUPPORT51.89
SUPPORT51.53
SUPPORT51.17
SUPPORT50.59
 
ORNBV Forecast February 2025
4th UP Forecast59.57
3rd UP Forecast57.27
2nd UP Forecast55.85
1st UP Forecast54.43
1st DOWN Forecast50.37
2nd DOWN Forecast48.95
3rd DOWN Forecast47.53
4th DOWN Forecast45.23
 
ORNBV Weekly Forecast
4th UP Forecast58.76
3rd UP Forecast56.72
2nd UP Forecast55.46
1st UP Forecast54.20
1st DOWN Forecast50.60
2nd DOWN Forecast49.34
3rd DOWN Forecast48.08
4th DOWN Forecast46.04
 
ORNBV Forecast2025
4th UP Forecast93.33
3rd UP Forecast80.2
2nd UP Forecast72.09
1st UP Forecast63.98
1st DOWN Forecast40.82
2nd DOWN Forecast32.71
3rd DOWN Forecast24.6
4th DOWN Forecast11.47
 
 
ORNBV Other Details
Segment EQ
Market Capital 5253615616.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
ORNBV Address
ORNBV
 
ORNBV Latest News
 
Your Comments and Response on Orion Oyj
 
ORNBV Business Profile
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland. Address: Orionintie 1A, Espoo, Finland, 02200
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service